title: Treatment of rat fibrosarcoma by radiotherapy plus immune adjuvant.
abstract: Combined radiotherapy and nonspecific adjuvant C. parvum or Piromen treatment of rat tumors show improvement over radiotherapy alone. The most effective protocol, resulting in complete remission in 6 of 6 rats was obtained with C. parvum given i.p. in three doses 1 day prior to tumor X-irradiation of three doses of 1500 R each given on days 1, 4, and 8. Animals receiving the same dose schedule without adjuvant had only partial regression of their tumor. Without adjuvant, increasing the dose to 6000 R also resulted in tumor regression, but at the expense of marked necrosis to the leg. One mechanism for the observed results may be stimulation of the reticulo-endothelial system to produce macrophages activated against the tumor. It is also possible that C. parvum causes increased rate of clearance of soluble antigens released as a result of radiation destruction of the tumor, as suggested by Proctor et al (3).
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D001500:BCG Vaccine / Q000627:therapeutic use; D005354:Fibrosarcoma / Q000532:radiotherapy / Q000628:therapy*; D011135:Polysaccharides, Bacterial / Q000627:therapeutic use; D011425:Propionibacterium acnes / Q000276:immunology; D011549:Pseudomonas / Q000276:immunology; D011879:Radiotherapy Dosage; D051381:Rats; D012075:Remission, Spontaneous; D012513:Sarcoma, Experimental / Q000532:radiotherapy / Q000628:therapy; D013997:Time Factors; D014964:X-Ray Therapy; D015054:Zymosan / Q000627:therapeutic use
chemical_list: D000276:Adjuvants, Immunologic; D001500:BCG Vaccine; D011135:Polysaccharides, Bacterial; D015054:Zymosan